Realta Life Sciences, Inc.
✓ AI-Ready Profile81
AI Score
🤖 AI-Optimized Summary
ReAlta advances pegtarazimod, a Phase 2 therapy targeting hypoxic ischemic encephalopathy (HIE) to protect the newborn brain and preserve lifelong function.
📋 Business Details
Is this your business?
Claim this profile to improve your AI Visibility Score and get verified.
Claim My AI Profile →